Last $139.50 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 4:30 PM 05/5/14 All times are local (Market data is delayed by at least 15 minutes).

alk-abello a/s (AKBLF) Snapshot

Open
--
Previous Close
$139.50
Day High
--
Day Low
--
52 Week High
04/22/14 - $141.50
52 Week Low
08/21/13 - $82.25
Market Cap
1.5B
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
9.2M
EX-Date
03/13/14
P/E TM
--
Dividend
$5.16
Dividend Yield
0.67%
Current Stock Chart for ALK-ABELLO A/S (AKBLF)

Related News

No related news articles were found.

alk-abello a/s (AKBLF) Related Businessweek News

No Related Businessweek News Found

alk-abello a/s (AKBLF) Details

ALK-Abelló A/S, a pharmaceutical company, engages in the research and development, production, and sale of products for the diagnosis, prevention, and treatment of allergies. The company offers allergy immunotherapy products as injections, sublingual drops, and tablets. It provides GRAZAX, a tablet-based vaccine for grass pollen allergy; SLITone, a droplet-based allergy vaccine for daily administration through a single-dose container; and Alutard SQ, a product for subcutaneous allergy vaccination. The company’s products also include JEXT, an adrenaline auto-injector used to treat acute allergic reactions; and AVANZ, an injection based immunotherapy product. Its products in pipeline comprise Grass AIT, which has completed Phase III clinical trial for the treatment of grass allergic rhinoconjunctivitis (ARC); GRAZAX that is in Phase III clinical trial for asthma prevention; Ragweed AIT, a Phase III clinical trial product for ragweed ARC; HDM AIT for the treatment of house dust mite asthma and rhinitis; and Tree AIT, a Phase II clinical trial product for the treatment of tree ARC. In addition, the company focuses on developing AIT products against Japanese cedar pollen allergy; and products for cat allergies, as well as manufactures allergen extracts for allergy testing, such as skin-prick tests. The company provides its products through distributors worldwide. ALK-Abelló A/S has partnership agreements with Merck & Co., Inc. and Torii Pharmaceutical Co., Ltd. to develop, register, and commercialize tablets in North America and Japan. The company was founded in 1923 and is headquartered in Hørsholm, Denmark.

1,782 Employees
Last Reported Date: 05/8/14
Founded in 1923

alk-abello a/s (AKBLF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

alk-abello a/s (AKBLF) Key Developments

ALK-Abelló A/S Appoints Helle Skov as New Executive Vice President (Product Supply) and Member of the Board of Management, Effective October 1, 2014

ALK announced the appointment of Helle Skov as new Executive Vice President (Product Supply) and member of the Board of Management of ALK-Abelló A/S. Helle Skov will be responsible for ALK's Product Supply with production sites in Denmark, Spain, France, the Netherlands and the USA. She joins ALK from a position as Vice President and Head of Global Supply Chain, Takeda. Helle Skov will start at ALK no later than 1 October 2014.

ALK's Partner Torii Pharmaceutical Co., Ltd. Announces Trial Results for House Dust Mite SLIT-Tablet

ALK announced that its partner for Japan, Torii Pharmaceutical Co., Ltd. has completed its second of two Phase II/III trials into ALK's sublingual allergy immunotherapy tablet (SLIT-tablet) for the treatment of house dust mite (HDM)-induced respiratory diseases. Torii initiated the trial in 2012 as a randomised, multi-centre, placebo-controlled, double-blind comparative trial, looking at both the safety and efficacy of the drug in patients with house dust mite-induced allergic asthma. While the trial confirmed that the treatment was well tolerated by patients, with no new or unexpected findings reported, the trial did not meet the primary efficacy endpoint of showing a statistically significantly lower risk of moderate to severe asthma exacerbations when compared with patients who received placebo. A parallel trial, investigating the safety and efficacy in HDM-induced allergic rhinitis was successfully completed in March 2014 and met its primary efficacy endpoint. In all, approximately 1,800 patients have participated in the two Japanese clinical trials. Torii will now seek to discuss the trial results, along with relevant supportive documentation from ALK's European development programme, with the Japanese health authorities. Based on the available data, Torii expects to submit a registration application to the authorities within the next six-to-ten months.

ALK-Abelló A/S - Shareholder/Analyst Call

ALK-Abelló A/S - Shareholder/Analyst Call

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AKBLF:US $139.50 USD 0.00

AKBLF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergy Therapeutics PLC 19.38 GBp +0.25
DBV Technologies SA €19.89 EUR -0.18
Merck & Co Inc $58.15 USD -0.06
Sanofi €75.98 EUR -1.34
Stallergenes SA €53.50 EUR +2.24
View Industry Companies
 

Industry Analysis

AKBLF

Industry Average

Valuation AKBLF Industry Range
Price/Earnings 60.5x
Price/Sales 3.3x
Price/Book 3.3x
Price/Cash Flow 56.8x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALK-ABELLO A/S, please visit www.alk-abello.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.